The clinical-stage biotech filed for Chapter 11 bankruptcy after several pipeline flops, including an issue with its experimental acne drug SNA-001 in 2017, according to EndPoints News.
“We believe this decision is in the best interests of Sienna and its stakeholders,” said Frederick Beddingfield III, MD, PhD, president and CEO of Sienna, in a news release. “The protections afforded by Chapter 11 provide for an orderly restructuring process as well as additional time to pursue financial and strategic alternatives.”
Sienna expects to maintain business operations while looking for a strategic partner or purchaser.
It listed its assets at $107.6 million and debts at $80.7 million in its Chapter 11 bankruptcy petition.
More articles on pharmacy:
Purdue Pharma files for bankruptcy
DEA proposes to cut opioid production in half
Pharmacist-led HIV prevention treatment program could boost patient satisfaction, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
